TTR and Fabry disease: Appropriate aetiological diagnosis of HCM, and reduction in the time of the process, is key issue, especially for some diseases such as ATTR amyloidosis or Fabry disease, where specific therapies are recommended (Tafamidis for ATTR or enzyme replacement therapies or chaperone therapy in Fabry disease).